Research network The Nordic Prostate Cancer Precision Medicine Forum is a research network collaborating to advance precision medicine tools in prostate cancer.
The aim of the research is to develop refined and validated predictive biomarkers, building on the participating groups’ previous work and shared expertise. The project is funded through a grant of €1.6 million from EP PerMed under the call “Pharmacogenomic strategies for personalized medicine approaches.”
Prognostic and predictive transcription panels developed by members of the consortium will be transformed using spatial multi-omics methodologies at the spatial single-cell level. This approach will refine the tools for optimal performance in relation to the tissue’s structural heterogeneity, followed by validation in joint cohorts and purpose-designed study framework.
Project consortium - Members
Joakim Lundeberg, KTH, Sweden
Morten Beck Rye, Norwegian University of Science and Technology
Kristin Austlid Taskén, Oslo University
Klaus Brasso, University of Copenhagen
Toumas Mirtti, University of Helsinki
Magnus Klang, Swedish Prostate Cancer Federation
Co-applicants
Sweden: Pernilla Wikström, Karin Welén
Sweden patient representative organization: Magnus Klang and Hans Joelsson
Finland: Andrew Erickson
Denmark: Andreas Röder and Hein Vincent Stroomberg
Norway: May-Britt Tessem and Ieva Ailte
